Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781555 | 0.83 | THRB (0.44) | THRBALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL3446620 | 0.81 | ALDH1A1 (0.52) | THRBALDH1A1TSHRHSD17B10 | |
| SCHEMBL1419614 | 0.80 | THRB (0.45) | THRBALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL25389391 | 0.78 | TDP1 (0.52) | THRBALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL27550157 | 0.78 | ALDH1A1 (0.41) | THRBALDH1A1TSHR | |
| SCHEMBL7642768 | 0.78 | ALDH1A1 (0.41) | THRBALDH1A1TSHR | |
| SCHEMBL15514061 | 0.77 | THRB (0.42) | THRBALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL3400820 | 0.77 | ALDH1A1 (0.48) | THRBALDH1A1TSHRHSD17B10 | |
| SCHEMBL5702010 | 0.76 | TSHR (0.38) | THRBALDH1A1TSHR | |
| SCHEMBL7640405 | 0.75 | THRB (0.46) | THRBALDH1A1TSHRMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112789065-A | Medical device | 微仙美国有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20080038679-A1 | DEVELOPING AGENT AND MANUFACTURING METHOD THEREOF | KABUSHIKI KAISHA TOSHIBA (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | ELOVL1, ELOVL6, DEGS1 | THRB 4533/4885ALDH1A1 402/4885TSHR 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.